Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07053436 · ClinicalTrials.gov registry record · Phase 2
Horizon Two: HR NDMM (MMRC-100)
A Phase 2 study, sponsored by Multiple Myeloma Research Consortium.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 300
- Enrollment target
NCT07053436 is a Phase 2 study that is actively recruiting participants, run by Multiple Myeloma Research Consortium. The registered enrollment target is 300 participants.
The verdict
NCT07053436, a Phase 2 study, is actively recruiting participants, sponsored by Multiple Myeloma Research Consortium.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 300 participants
- Enrollment target
Study Summary
The Multiple Myeloma Research Consortium (MMRC) Horizon Two trial is a master protocol, multi-center, phase II randomized adaptive platform trial designed to efficiently evaluate multiple investigational therapies in high-risk newly diagnosed multiple myeloma patients using an integrated and patient-centric clinical research platform that enables longitudinal learning and sharing of knowledge and investigates multiple novel therapeutic strategies within one trial platform.
Interventions
- DRUG Bispecific Monoclonal Antibody and Triplet Therapy
- DRUG Monoclonal Antibody with Stem Cell Transplant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2026-04-30 |
| Est. Completion | 2035-10-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07053436
The ClinicalTrials.gov registry entry for NCT07053436 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Multiple Myeloma Research Consortium, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Bispecific Monoclonal Antibody and Triplet Therapy is the first listed.
NCT07053436 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07053436 about?
NCT07053436 is a clinical study titled "Horizon Two: HR NDMM (MMRC-100)". The Multiple Myeloma Research Consortium (MMRC) Horizon Two trial is a master protocol, multi-center, phase II randomized adaptive platform trial designed to efficiently evaluate multiple investigational therapies in high-risk newly diagnosed multiple myeloma patients using an integrated and patient...
What is the current status of trial NCT07053436?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 300 participants. The study started on 2026-04-30. Estimated completion is 2035-10-12.
What interventions are being tested in trial NCT07053436?
The interventions under investigation include: Bispecific Monoclonal Antibody and Triplet Therapy (DRUG), Monoclonal Antibody with Stem Cell Transplant (DRUG).
Who is sponsoring clinical trial NCT07053436?
This trial is sponsored by Multiple Myeloma Research Consortium, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.